We recently published 10 Most Undervalued Pharma Stocks To Buy Now. AstraZeneca PLC stands fifth on our list among the most undervalued stocks. AstraZeneca PLC (NASDAQ:AZN), a global biopharmaceutical ...

Anselamimab, which AstraZeneca acquired via Caelum Biosciences, missed its primary goal in two late-stage trials, but appeared to have some benefit in a subgroup of patients.

AstraZeneca PLC (NASDAQ:AZN) is one of the 10 best defensive stocks to buy in a volatile market. On July 4, the company entered into a multi-year agreement with Modella AI. The two are joining ...

AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for AAV capsids from existing partner JCR Pharmaceuticals.

AstraZeneca’s stock market exit would be devastating blow, warns ex-chancellor The UK is ‘a hostile environment’ for innovative, high-tech growth companies, the Government has been told.

AstraZeneca may have washed its hands of AZD4041 after the opioid use disorder (OUD) prospect demonstrated a potential drug-drug interaction last year, but the pharma’s development partner ...

AstraZeneca announced a final dividend of Rs 32 per share, with the ex-date due tomorrow, July 18, 2025. This makes today the last day to buy the shares for dividend eligibility, or to trade the ...

Amid $15B AstraZeneca partnership rumor, Summit needs $7.7B upfront to excite investors: analyst By Angus Liu Jul 7, 2025 10:45am AstraZeneca Summit Therapeutics M&A Licensing deals ...

AstraZeneca chief executive Pascal Soriot is reportedly considering moving the company's stock exchange listing from the UK to the US.

AstraZeneca PLC (NASDAQ:AZN) is one of Goldman Sachs’ top healthcare stock picks. On July 4, the company secured regulatory approval for Imfinzi (durvalumab).